PF ‐06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity

Mitochondria-targeted drugs for diabetic kidney disease

(2022) Akira Mima   Heliyon

Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease

(2022) Xudong Cao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease

(2022) Haoran Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

PF-06409577 Activates AMPK Signaling and Inhibits Osteosarcoma Cell Growth

(2021) Yun-Rong Zhu et al.   Frontiers in Oncology

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis

(2020) Jinzhao He et al.   PHARMACOLOGICAL RESEARCH

Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes

(2020) Akira Mima et al.   Scientific Reports

Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo

(2020) Ines Cabrita et al.   Nature Communications

Autosomal dominant polycystic kidney disease

(2019) Emilie Cornec-Le Gall et al.   LANCET

Aquaporin-3 deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease

(2019) Weiling Wang et al.   FASEB JOURNAL

Metformin in 2019

(2019) James Flory et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The pathobiology of polycystic kidney disease from a metabolic viewpoint

(2019) Luis Fernando Menezes et al.   Nature Reviews Nephrology

Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease

(2019) Wouter N. Leonhard et al.   EBioMedicine

The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium

(2019) Jean Piero Margaria et al.   CELLULAR SIGNALLING

Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models

(2018) Ryan M. Esquejo et al.   EBioMedicine

Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease

(2018) Fouad T. Chebib et al.   Clinical Journal of the American Society of Nephrology

The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease

(2018) Xiaoying Lian et al.   BRITISH JOURNAL OF PHARMACOLOGY

Polycystic kidney disease

(2018) Carsten Bergmann et al.   Nature Reviews Disease Primers

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease

(2017) Vladimir Tesar et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation

(2017) Limin Su et al.   KIDNEY INTERNATIONAL

Metformin; a review of its history and future: from lilac to longevity

(2017) Inas Thomas et al.   PEDIATRIC DIABETES

Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy

(2016) Kimberly O. Cameron et al.   JOURNAL OF MEDICINAL CHEMISTRY

AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs

(2016) D. Grahame Hardie et al.   TRENDS IN CELL BIOLOGY

Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease

(2015) C. S. Pinto et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

(2013) Anna Caroli et al.   LANCET

Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy

(2012) Akira Mima et al.   FASEB JOURNAL

Glomerular-specific protein kinase C-β-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity

(2011) Akira Mima et al.   KIDNEY INTERNATIONAL

Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis

(2011) V. Takiar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The cell biology of polycystic kidney disease

(2010) Hannah C. Chapin et al.   JOURNAL OF CELL BIOLOGY

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

(2010) Marc Foretz et al.   JOURNAL OF CLINICAL INVESTIGATION

Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease

(2010) Andreas L. Serra et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1

(2008) Sekiya Shibazaki et al.   HUMAN MOLECULAR GENETICS